Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details)

v3.23.3
Summary of Significant Accounting Policies (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Summary of Significant Accounting Policies (Details) [Line Items]          
Foreign currency translation description     The functional currency of certain subsidiaries was the British Pound (“GBP”) (1.2386 and 1.2098 GBP to 1 US dollar, each as of September 30, 2023 and December 31, 2022, respectively) for balance sheet accounts, while expense accounts are translated at the weighted average exchange rate for the period (1.2655 and 1.1772 GBP to 1 US dollar for each of the three months ended September 30, 2023 and 2022, respectively, and 1.2442 and 1.2597 GBP to 1 US dollar each for the nine months ended September 30, 2023 and 2022, respectively). Equity accounts are translated at historical exchange rates. The resulting translation adjustments are recognized in stockholders’ (deficit) equity as a component of accumulated other comprehensive (loss) income.    
Comprehensive loss $ 51,316 $ (1,871,072) $ 36,712 $ (4,507,204)  
Foreign currency transaction gain (losses) (2,952) $ (1,485) (14,031) $ (14,151)  
Asset carrying amount         $ 12,405,084
Fair market value         (9,063,000)
Assets impaired         3,342,084
In-process research and development     9,063,000
In-process research and development after impairment         9,063,000
Loss on impairment     9,063,000    
In-process research and development assets 2,300,000   2,300,000    
Minimum [Member]          
Summary of Significant Accounting Policies (Details) [Line Items]          
Fair market value         0
Assets exceeded market values         1,462,084
In-process research and development         0
Maximum [Member]          
Summary of Significant Accounting Policies (Details) [Line Items]          
Fair market value         9,063,000
Assets exceeded market values         1,880,000
In-process research and development         9,063,000
Revision of Prior Period, Accounting Standards Update, Adjustment [Member]          
Summary of Significant Accounting Policies (Details) [Line Items]          
In-process research and development 9,063,000   9,063,000    
In Process Research and Development [Member]          
Summary of Significant Accounting Policies (Details) [Line Items]          
In-process research and development $ 0   $ 0    
CBR Pharma [Member]          
Summary of Significant Accounting Policies (Details) [Line Items]          
Asset carrying amount         1,462,084
180 LP [Member]          
Summary of Significant Accounting Policies (Details) [Line Items]          
Asset carrying amount         $ 10,943,000